Published in J Exp Med on October 02, 2000
Neoadjuvant Anti-PD-1, Nivolumab in Resectable NSCLC (NA_00092076) | NCT02259621
Neoadjuvant Immune Checkpoint Blockade in Resectable Malignant Pleural Mesothelioma | NCT03918252
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med (2012) 52.99
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med (2012) 35.24
The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer (2012) 24.94
Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci Transl Med (2012) 13.12
Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci U S A (2002) 12.39
Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol (2014) 9.86
Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses. Immunity (2007) 8.94
Immunosuppressive strategies that are mediated by tumor cells. Annu Rev Immunol (2007) 8.31
PD-1 is a regulator of virus-specific CD8+ T cell survival in HIV infection. J Exp Med (2006) 8.18
Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer. Proc Natl Acad Sci U S A (2007) 7.49
Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity. Curr Opin Immunol (2012) 7.26
B7-DC, a new dendritic cell molecule with potent costimulatory properties for T cells. J Exp Med (2001) 6.97
Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired. Blood (2009) 6.17
Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma. J Exp Med (2003) 6.06
The PD-1 pathway in tolerance and autoimmunity. Immunol Rev (2010) 5.99
Resolution of a chronic viral infection after interleukin-10 receptor blockade. J Exp Med (2006) 4.97
PD-L1-deficient mice show that PD-L1 on T cells, antigen-presenting cells, and host tissues negatively regulates T cells. Proc Natl Acad Sci U S A (2004) 4.75
Autoimmune T cell responses in the central nervous system. Nat Rev Immunol (2009) 4.73
Overall Survival and Long-Term Safety of Nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer. J Clin Oncol (2015) 4.68
Immune Checkpoint Blockade in Cancer Therapy. J Clin Oncol (2015) 4.25
The programmed death-1 (PD-1) pathway regulates autoimmune diabetes in nonobese diabetic (NOD) mice. J Exp Med (2003) 4.20
Reinvigorating exhausted HIV-specific T cells via PD-1-PD-1 ligand blockade. J Exp Med (2006) 4.17
Checkpoint blockade in cancer immunotherapy. Adv Immunol (2006) 4.09
Global genomic analysis reveals rapid control of a robust innate response in SIV-infected sooty mangabeys. J Clin Invest (2009) 3.55
The B7-H1 (PD-L1) T lymphocyte-inhibitory molecule is expressed in breast cancer patients with infiltrating ductal carcinoma: correlation with important high-risk prognostic factors. Neoplasia (2006) 3.54
PD-1 regulates germinal center B cell survival and the formation and affinity of long-lived plasma cells. Nat Immunol (2010) 3.51
PD-L1 expression is characteristic of a subset of aggressive B-cell lymphomas and virus-associated malignancies. Clin Cancer Res (2013) 3.48
PD-1 immunoreceptor inhibits B cell receptor-mediated signaling by recruiting src homology 2-domain-containing tyrosine phosphatase 2 to phosphotyrosine. Proc Natl Acad Sci U S A (2001) 3.32
PD-1 inhibits antiviral immunity at the effector phase in the liver. J Exp Med (2003) 3.05
PD-L1 and PD-L2 are differentially regulated by Th1 and Th2 cells. Proc Natl Acad Sci U S A (2003) 3.02
Interaction between B7-H1 and PD-1 determines initiation and reversal of T-cell anergy. Blood (2007) 3.00
Critical role of the programmed death-1 (PD-1) pathway in regulation of experimental autoimmune encephalomyelitis. J Exp Med (2003) 3.00
Functional restoration of HCV-specific CD8 T cells by PD-1 blockade is defined by PD-1 expression and compartmentalization. Gastroenterology (2008) 2.95
Role of PD-1 and its ligand, B7-H1, in early fate decisions of CD8 T cells. Blood (2007) 2.93
Programmed death 1 ligand signaling regulates the generation of adaptive Foxp3+CD4+ regulatory T cells. Proc Natl Acad Sci U S A (2008) 2.73
Activated monocytes in peritumoral stroma of hepatocellular carcinoma foster immune privilege and disease progression through PD-L1. J Exp Med (2009) 2.73
Safety, efficacy, and biomarkers of nivolumab with vaccine in ipilimumab-refractory or -naive melanoma. J Clin Oncol (2013) 2.70
The programmed death-1 ligand 1:B7-1 pathway restrains diabetogenic effector T cells in vivo. J Immunol (2011) 2.69
B7x: a widely expressed B7 family member that inhibits T cell activation. Proc Natl Acad Sci U S A (2003) 2.66
Molecular modeling and functional mapping of B7-H1 and B7-DC uncouple costimulatory function from PD-1 interaction. J Exp Med (2003) 2.66
Expression of programmed death ligand 1 (PD-L1) is associated with poor prognosis in human breast cancer. Breast Cancer Res Treat (2014) 2.61
Programmed cell death 1 forms negative costimulatory microclusters that directly inhibit T cell receptor signaling by recruiting phosphatase SHP2. J Exp Med (2012) 2.58
PD-1/PD-L1 interactions inhibit antitumor immune responses in a murine acute myeloid leukemia model. Blood (2009) 2.54
A rheostat for immune responses: the unique properties of PD-1 and their advantages for clinical application. Nat Immunol (2013) 2.50
Expression and regulation of the PD-L1 immunoinhibitory molecule on microvascular endothelial cells. Microcirculation (2002) 2.49
Interaction of human PD-L1 and B7-1. Mol Immunol (2008) 2.48
Interleukin-27 priming of T cells controls IL-17 production in trans via induction of the ligand PD-L1. Immunity (2012) 2.47
From genes to drugs: targeted strategies for melanoma. Nat Rev Cancer (2012) 2.46
The biology of human lymphoid malignancies revealed by gene expression profiling. Adv Immunol (2005) 2.42
B7-H1 is a ubiquitous antiapoptotic receptor on cancer cells. Blood (2008) 2.41
Early resolution of acute immune activation and induction of PD-1 in SIV-infected sooty mangabeys distinguishes nonpathogenic from pathogenic infection in rhesus macaques. J Immunol (2008) 2.39
T cells from CLL patients exhibit features of T-cell exhaustion but retain capacity for cytokine production. Blood (2012) 2.37
The novel costimulatory programmed death ligand 1/B7.1 pathway is functional in inhibiting alloimmune responses in vivo. J Immunol (2011) 2.34
PD-L1 expression in the Merkel cell carcinoma microenvironment: association with inflammation, Merkel cell polyomavirus and overall survival. Cancer Immunol Res (2013) 2.30
Prostate cancer as a model for tumour immunotherapy. Nat Rev Immunol (2010) 2.28
In vivo costimulatory role of B7-DC in tuning T helper cell 1 and cytotoxic T lymphocyte responses. J Exp Med (2005) 2.28
Combination cancer immunotherapy and new immunomodulatory targets. Nat Rev Drug Discov (2015) 2.25
Human prostate-infiltrating CD8+ T lymphocytes are oligoclonal and PD-1+. Prostate (2009) 2.17
PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations. Sci Transl Med (2016) 2.16
Mechanisms maintaining peripheral tolerance. Nat Immunol (2009) 2.14
A critical role for the programmed death ligand 1 in fetomaternal tolerance. J Exp Med (2005) 2.13
Programmed death-1 (PD-1)-deficient mice are extraordinarily sensitive to tuberculosis. Proc Natl Acad Sci U S A (2010) 2.12
PD-1 is a regulator of NY-ESO-1-specific CD8+ T cell expansion in melanoma patients. J Immunol (2009) 2.12
Immunotherapy of cancer in 2012. CA Cancer J Clin (2012) 2.12
Early window of diabetes determinism in NOD mice, dependent on the complement receptor CRIg, identified by noninvasive imaging. Nat Immunol (2012) 2.11
The PD-1/PD-L1 complex resembles the antigen-binding Fv domains of antibodies and T cell receptors. Proc Natl Acad Sci U S A (2008) 2.03
Simultaneous blockade of multiple immune system inhibitory checkpoints enhances antitumor activity mediated by interleukin-15 in a murine metastatic colon carcinoma model. Clin Cancer Res (2010) 1.92
B7DC/PDL2 promotes tumor immunity by a PD-1-independent mechanism. J Exp Med (2003) 1.92
At the bedside: CTLA-4- and PD-1-blocking antibodies in cancer immunotherapy. J Leukoc Biol (2013) 1.90
Costimulating aberrant T cell responses by B7-H1 autoantibodies in rheumatoid arthritis. J Clin Invest (2003) 1.87
Cooperative B7-1/2 (CD80/CD86) and B7-DC costimulation of CD4+ T cells independent of the PD-1 receptor. J Exp Med (2003) 1.85
The role of herpesvirus entry mediator as a negative regulator of T cell-mediated responses. J Clin Invest (2005) 1.82
Expression of programmed cell death ligand 1 is associated with poor overall survival in patients with diffuse large B-cell lymphoma. Blood (2015) 1.80
Programmed death-1 levels correlate with increased mortality, nosocomial infection and immune dysfunctions in septic shock patients. Crit Care (2011) 1.78
PD-1 on dendritic cells impedes innate immunity against bacterial infection. Blood (2009) 1.74
The B7 family of immune-regulatory ligands. Genome Biol (2005) 1.74
B7-H1 (PD-L1, CD274) suppresses host immunity in T-cell lymphoproliferative disorders. Blood (2009) 1.74
The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma. Clin Ther (2015) 1.73
Dendritic cell-mediated T cell polarization. Springer Semin Immunopathol (2004) 1.72
B7-H3 is a potent inhibitor of human T-cell activation: No evidence for B7-H3 and TREML2 interaction. Eur J Immunol (2009) 1.71
CD4 T cells promote rather than control tuberculosis in the absence of PD-1-mediated inhibition. J Immunol (2010) 1.71
Local expression of B7-H1 promotes organ-specific autoimmunity and transplant rejection. J Clin Invest (2004) 1.71
Immunotherapy earns its spot in the ranks of cancer therapy. J Exp Med (2012) 1.71
Responsiveness of HIV-specific CD4 T cells to PD-1 blockade. Blood (2011) 1.70
Activation and inhibition of lymphocytes by costimulation. J Clin Invest (2002) 1.69
The emerging role of resident memory T cells in protective immunity and inflammatory disease. Nat Med (2015) 1.69
Anti-PD-1/PD-L1 therapy of human cancer: past, present, and future. J Clin Invest (2015) 1.67
FOXP3+ Tregs and B7-H1+/PD-1+ T lymphocytes co-infiltrate the tumor tissues of high-risk breast cancer patients: Implication for immunotherapy. BMC Cancer (2008) 1.63
Functionally distinct LAG-3 and PD-1 subsets on activated and chronically stimulated CD8 T cells. J Immunol (2009) 1.60
Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway. Trends Mol Med (2014) 1.59
Harnessing the immune system to treat cancer. J Clin Invest (2007) 1.57
Constitutive and inducible expression of b7 family of ligands by human airway epithelial cells. Am J Respir Cell Mol Biol (2005) 1.56
Biomarkers in early-stage non-small-cell lung cancer: current concepts and future directions. J Thorac Oncol (2014) 1.56
The level of B7 homologue 1 expression on brain DC is decisive for CD8 Treg cell recruitment into the CNS during EAE. Eur J Immunol (2009) 1.55
Crystal structure of the complex between programmed death-1 (PD-1) and its ligand PD-L2. Proc Natl Acad Sci U S A (2008) 1.55
Batf3-dependent dendritic cells in the renal lymph node induce tolerance against circulating antigens. J Am Soc Nephrol (2013) 1.54
PD-L1 and PD-L2 modulate airway inflammation and iNKT-cell-dependent airway hyperreactivity in opposing directions. Mucosal Immunol (2009) 1.53
B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion. Nat Med (1999) 16.91
Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4. Science (1995) 16.19
Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity (1995) 14.90
Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity (1999) 12.36
Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family. Cell (1993) 9.06
Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J (1992) 8.86
Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes. Int Immunol (1996) 6.79
The emerging role of CTLA-4 as an immune attenuator. Immunity (1997) 5.35
T-cell co-stimulation through B7RP-1 and ICOS. Nature (1999) 4.20
Immunological studies on PD-1 deficient mice: implication of PD-1 as a negative regulator for B cell responses. Int Immunol (1998) 4.14
Selective induction of B7/BB-1 on interferon-gamma stimulated monocytes: a potential mechanism for amplification of T cell activation through the CD28 pathway. Cell Immunol (1991) 3.12
B7h, a novel costimulatory homolog of B7.1 and B7.2, is induced by TNFalpha. Immunity (1999) 2.94
CTLA-4 and CD28 activated lymphocyte molecules are closely related in both mouse and human as to sequence, message expression, gene structure, and chromosomal location. J Immunol (1991) 2.92
Immunoreceptor tyrosine-based inhibition motifs. Immunol Today (1997) 2.46
Structure and dimerization of a soluble form of B7-1. Immunity (2000) 2.33
Cutting edge: identification of GL50, a novel B7-like protein that functionally binds to ICOS receptor. J Immunol (2000) 2.13
The complexities of T-cell co-stimulation: CD28 and beyond. Immunol Rev (1996) 2.08
CTLA-4 ligation delivers a unique signal to resting human CD4 T cells that inhibits interleukin-2 secretion but allows Bcl-X(L) induction. J Immunol (1998) 2.01
Structure and chromosomal localization of the human PD-1 gene (PDCD1). Genomics (1994) 1.96
Discordant expression of CD28 ligands, BB-1, and B7 on keratinocytes in vitro and psoriatic cells in vivo. Am J Pathol (1993) 1.94
CTLA-4 and CD28 mRNA are coexpressed in most T cells after activation. Expression of CTLA-4 and CD28 mRNA does not correlate with the pattern of lymphokine production. J Immunol (1992) 1.91
Structure and evolution of the extended B7 family. Immunol Today (1999) 1.90
Activation-induced expression of human programmed death-1 gene in T-lymphocytes. Exp Cell Res (1997) 1.85
The role of B7-1/B7-2:CD28/CLTA-4 pathways in the prevention of anergy, induction of productive immunity and down-regulation of the immune response. Immunol Rev (1996) 1.76
The costimulatory genes Cd80 and Cd86 are linked on mouse chromosome 16 and human chromosome 3. Mamm Genome (1997) 1.59
The BB1 monoclonal antibody recognizes both cell surface CD74 (MHC class II-associated invariant chain) as well as B7-1 (CD80), resolving the question regarding a third CD28/CTLA-4 counterreceptor. J Immunol (1998) 1.49
Characterization of murine Flt4 ligand/VEGF-C. Oncogene (1997) 1.46
Expression monitoring by hybridization to high-density oligonucleotide arrays. Nat Biotechnol (1996) 72.84
Class switch recombination and hypermutation require activation-induced cytidine deaminase (AID), a potential RNA editing enzyme. Cell (2000) 20.83
Complete genome sequence of the model actinomycete Streptomyces coelicolor A3(2). Nature (2002) 19.35
The genome sequence of Schizosaccharomyces pombe. Nature (2002) 14.26
Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity (1999) 12.36
PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nat Immunol (2001) 12.26
Activation-induced cytidine deaminase (AID) deficiency causes the autosomal recessive form of the Hyper-IgM syndrome (HIGM2). Cell (2000) 9.99
Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J (1992) 8.86
Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice. Science (2001) 8.31
Uncertainty in predictions of the climate response to rising levels of greenhouse gases. Nature (2005) 7.46
A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim Biophys Acta (1976) 7.41
Notch signalling controls pancreatic cell differentiation. Nature (1999) 7.18
The biochemistry of P-glycoprotein-mediated multidrug resistance. Annu Rev Biochem (1989) 7.13
Mechanism of DNA chain growth. I. Possible discontinuity and unusual secondary structure of newly synthesized chains. Proc Natl Acad Sci U S A (1968) 6.82
Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes. Int Immunol (1996) 6.79
Specific expression of activation-induced cytidine deaminase (AID), a novel member of the RNA-editing deaminase family in germinal center B cells. J Biol Chem (1999) 6.67
Microbial lipopeptides induce the production of IL-17 in Th cells. J Immunol (2000) 5.74
Complete nucleotide sequence of mouse immunoglobulin mu gene and comparison with other immunoglobulin heavy chain genes. Nucleic Acids Res (1980) 5.20
Transformation of Arabidopsis thaliana with Agrobacterium tumefaciens. Science (1986) 5.20
Cloning and complete nucleotide sequence of mouse immunoglobulin gamma 1 chain gene. Cell (1979) 5.04
Molecular cloning of cDNA encoding human interleukin-2 receptor. Nature (1984) 4.95
IL-13, IL-4Ralpha, and Stat6 are required for the expulsion of the gastrointestinal nematode parasite Nippostrongylus brasiliensis. Immunity (1998) 4.65
Signal sequence trap: a cloning strategy for secreted proteins and type I membrane proteins. Science (1993) 4.64
The ubiquitin pathway in Parkinson's disease. Nature (1998) 4.48
A human centromere antigen (CENP-B) interacts with a short specific sequence in alphoid DNA, a human centromeric satellite. J Cell Biol (1989) 4.45
Fractionation and sequences of the large pyrimidine oligonucleotides from bacteriophage fd DNA. J Mol Biol (1972) 4.42
Generation of lymphohematopoietic cells from embryonic stem cells in culture. Science (1994) 4.41
An essential role in liver development for transcription factor XBP-1. Genes Dev (2000) 4.17
Immunological studies on PD-1 deficient mice: implication of PD-1 as a negative regulator for B cell responses. Int Immunol (1998) 4.14
Detection of P-glycoprotein in multidrug-resistant cell lines by monoclonal antibodies. Nature (1985) 3.97
Organization of immunoglobulin heavy chain genes and allelic deletion model. Proc Natl Acad Sci U S A (1978) 3.95
Bacillus sporulation gene spo0H codes for sigma 30 (sigma H). J Bacteriol (1988) 3.88
Cell surface P-glycoprotein associated with multidrug resistance in mammalian cell lines. Science (1983) 3.88
Diphtheria toxin-dependent adenosine diphosphate ribosylation of aminoacyl transferase II and inhibition of protein synthesis. J Biol Chem (1968) 3.81
Homology between P-glycoprotein and a bacterial haemolysin transport protein suggests a model for multidrug resistance. Nature (1987) 3.79
Pyrimidine sequences from the DNA of bacteriophages fd, fl, and phi X174. Proc Natl Acad Sci U S A (1972) 3.73
Organization of the constant-region gene family of the mouse immunoglobulin heavy chain. Cell (1982) 3.72
Immunoglobulin genes. Annu Rev Immunol (1983) 3.72
Rearrangement of immunoglobulin gamma 1-chain gene and mechanism for heavy-chain class switch. Proc Natl Acad Sci U S A (1980) 3.70
ICOS is critical for CD40-mediated antibody class switching. Nature (2001) 3.63
Structure and chromosomal localization of the human stromal cell-derived factor 1 (SDF1) gene. Genomics (1995) 3.60
Amplification of P-glycoprotein genes in multidrug-resistant mammalian cell lines. Nature (1985) 3.59
In situ class switching and differentiation to IgA-producing cells in the gut lamina propria. Nature (2001) 3.58
Construction of YAC-based mammalian artificial chromosomes. Nat Biotechnol (1998) 3.55
Physical interaction between a novel domain of the receptor Notch and the transcription factor RBP-J kappa/Su(H). Curr Biol (1995) 3.46
Obliquity-paced Pliocene West Antarctic ice sheet oscillations. Nature (2009) 3.42
Involvement of RBP-J in biological functions of mouse Notch1 and its derivatives. Development (1997) 3.42
Reduced permeability in CHO cells as a mechanism of resistance to colchicine. J Cell Physiol (1974) 3.36
Recognition sequence of a highly conserved DNA binding protein RBP-J kappa. Nucleic Acids Res (1994) 3.36
Nonadipose tissue production of leptin: leptin as a novel placenta-derived hormone in humans. Nat Med (1997) 3.35
A gene encoding a liver-specific ABC transporter is mutated in progressive familial intrahepatic cholestasis. Nat Genet (1998) 3.33
PD-1 immunoreceptor inhibits B cell receptor-mediated signaling by recruiting src homology 2-domain-containing tyrosine phosphatase 2 to phosphotyrosine. Proc Natl Acad Sci U S A (2001) 3.32
Disruption of the mouse RBP-J kappa gene results in early embryonic death. Development (1995) 3.30
Germline mutations in the Wilms' tumor suppressor gene are associated with abnormal urogenital development in Denys-Drash syndrome. Cell (1991) 3.19
TCGF (IL 2)-receptor inducing factor(s). I. Regulation of IL 2 receptor on a natural killer-like cell line (YT cells). J Immunol (1985) 3.18
Alymphoplasia is caused by a point mutation in the mouse gene encoding Nf-kappa b-inducing kinase. Nat Genet (1999) 3.17
Conservation of the Notch signalling pathway in mammalian neurogenesis. Development (1997) 3.13
Switch region of immunoglobulin Cmu gene is composed of simple tandem repetitive sequences. Nature (1981) 3.10
Multiple DNA fragment polymorphisms associated with immunoglobulin mu chain switch-like regions in man. Proc Natl Acad Sci U S A (1983) 3.07
Generation of polarized antigen-specific CD8 effector populations: reciprocal action of interleukin (IL)-4 and IL-12 in promoting type 2 versus type 1 cytokine profiles. J Exp Med (1994) 3.02
Plasma elevation of stromal cell-derived factor-1 induces mobilization of mature and immature hematopoietic progenitor and stem cells. Blood (2001) 3.01
Complete nucleotide sequence of immunoglobulin gamma2b chain gene cloned from newborn nouse DNA. Nature (1980) 2.97
A Drosophila homolog of cadherin associated with armadillo and essential for embryonic cell-cell adhesion. Dev Biol (1994) 2.94
Human centromere protein A (CENP-A) can replace histone H3 in nucleosome reconstitution in vitro. Proc Natl Acad Sci U S A (2000) 2.91
Repetitive sequences in class-switch recombination regions of immunoglobulin heavy chain genes. Cell (1981) 2.84
Mechanism of multidrug resistance. Biochim Biophys Acta (1988) 2.83
Alarming increase in dental sepsis. Br Dent J (2006) 2.74
The recombination signal sequence-binding protein RBP-2N functions as a transcriptional repressor. Mol Cell Biol (1994) 2.71
PD-1: an inhibitory immunoreceptor involved in peripheral tolerance. Trends Immunol (2001) 2.71
Nucleotide sequence divergence of mouse immunoglobulin gamma 1 and gamma 2b chain genes and the hypothesis of intervening sequence-mediated domain transfer. Proc Natl Acad Sci U S A (1980) 2.68
Delta-induced Notch signaling mediated by RBP-J inhibits MyoD expression and myogenesis. J Biol Chem (1999) 2.65
T-Independent immune response: new aspects of B cell biology. Science (2000) 2.63
Antiproteinuric effect of the calcium channel blocker cilnidipine added to renin-angiotensin inhibition in hypertensive patients with chronic renal disease. Kidney Int (2007) 2.61
Unequal death in T helper cell (Th)1 and Th2 effectors: Th1, but not Th2, effectors undergo rapid Fas/FasL-mediated apoptosis. J Exp Med (1997) 2.59
Overexpression and amplification of five genes in a multidrug-resistant Chinese hamster ovary cell line. Mol Cell Biol (1986) 2.59
FB elements are the common basis for the instability of the wDZL and wC Drosophila mutations. Cell (1982) 2.59
The murine IL-13 receptor alpha 2: molecular cloning, characterization, and comparison with murine IL-13 receptor alpha 1. J Immunol (1998) 2.57
The complete nucleotide sequence of the human immunoglobulin heavy chain variable region locus. J Exp Med (1998) 2.56
Expression of the Fas ligand in cells of T cell lineage. J Immunol (1995) 2.54
Antigen-induced apoptotic death of Ly-1 B cells responsible for autoimmune disease in transgenic mice. Nature (1992) 2.52